2024
Applying single-cell profiling to assess drug anti-fibrotic properties in the human precision-cut lung slice model of fibrosis
Justet A, Mitash M, Raredon S, Pineda R, Adams T, Al Hussein N, Ishizuka M, Hahram K, Khoury J, Ahangari F, Xiting Y, Naftali K, Melanie K. Applying single-cell profiling to assess drug anti-fibrotic properties in the human precision-cut lung slice model of fibrosis. 2024, oa1896. DOI: 10.1183/13993003.congress-2024.oa1896.Peer-Reviewed Original ResearchToll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024 PMID: 39189851, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelSingle-cell RNA-seq analysis of cell-cell communications in human lung reveals a novel role of VEGF-D in acute lung injury
Yuan Y, Sharma L, Tang W, Raredon M, Ahangari F, Khoury J, Wu D, Niklason L, Kaminski N. Single-cell RNA-seq analysis of cell-cell communications in human lung reveals a novel role of VEGF-D in acute lung injury. Physiology 2024, 39: 1314. DOI: 10.1152/physiol.2024.39.s1.1314.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisAcute lung injuryChronic obstructive pulmonary diseaseAcute respiratory distress syndromeAnalysis of cell-cell communicationVEGF-DMicrovascular nicheSingle-cell RNA-seqLung injury modelSingle-cell RNA-seq analysisLung injuryCell-cell communicationLigand-receptor pairsLPS-induced lung injury modelRNA-seqAdjacent cell typesPulmonary diseaseInjury modelHuman lung endothelial cellsBarrier functionImmune cell infiltrationTumor necrosis factor-aRespiratory distress syndromeLung vascular integrityGene expressionNebulizable Conjugates to Sustain Retention, Delivery, and Efficacy of Galectin-3 Inhibitory Drug TD139 in the Alveolar Space
Marti Munoz J, Khoury J, Ahangari F, Deiuliis G, Kaminski N, Pandit A. Nebulizable Conjugates to Sustain Retention, Delivery, and Efficacy of Galectin-3 Inhibitory Drug TD139 in the Alveolar Space. 2024, a3218-a3218. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3218.Peer-Reviewed Original ResearchVEGF-D Is Enriched in the Human Lung Microvascular Niche and Improves Vascular Integrity During Acute Lung Injury
Yuan Y, Sharma L, Tang W, Raredon M, Ahangari F, Khoury J, Wu D, Niklason L, Kaminski N. VEGF-D Is Enriched in the Human Lung Microvascular Niche and Improves Vascular Integrity During Acute Lung Injury. 2024, a4694-a4694. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4694.Peer-Reviewed Original ResearchProfibrotic Role of GPR87 in Pulmonary Fibrosis
Khoury J, Ahangari F, Manning E, Justet A, barnthaler T, Adams T, Necola F, Alysandratos K, Beermann M, Kotton D, Kaminski N. Profibrotic Role of GPR87 in Pulmonary Fibrosis. 2024, a5183-a5183. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5183.Peer-Reviewed Original ResearchApplying Single Cell Profiling to Assess Drug Anti Fibrotic Properties in the Human Precision Cut Lung Slice Model of Fibrosis
Justet A, Mitash N, Pineda R, Adams T, Balayev A, Abu Hussein N, Ishizuka M, Kim H, Khoury J, Ahangari F, Yan X, Kaminski N, Koenigshoff M. Applying Single Cell Profiling to Assess Drug Anti Fibrotic Properties in the Human Precision Cut Lung Slice Model of Fibrosis. 2024, a4906-a4906. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4906.Peer-Reviewed Original ResearchFibrotic cocktail treated human precision lung slices replicate the cellular diversity of the IPF lung
Justet A, Pineda H, Adams T, Balayev A, Mitash N, Ishizuka M, Kim H, Khoury J, Cala-García J, Flint J, Schupp J, Ahangari F, Yan X, Rosas I, Kaminski N, Königshoff M. Fibrotic cocktail treated human precision lung slices replicate the cellular diversity of the IPF lung. Revue Des Maladies Respiratoires 2024, 41: 218. DOI: 10.1016/j.rmr.2024.01.074.Peer-Reviewed Original ResearchCellular repertoireCell typesSingle cell platformsSequence readsCDNA libraryIllumina platformHuman genomeNucleus transcriptomicsCellular diversityIPF lungsPulmonary fibrosisEMT markersAirway epithelial cellsBasaloid cellsCellular populationsEpithelial cellsFibrotic fibroblastsCell platformLung slicesLung cell populationsHuman precision-cut lung slicesCell populationsSenescence markersCellsBasal markers
2023
Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study
Najjar-Debbiny R, Barnett-Griness O, Khoury J, Gronich N, Weber G, Adir Y, Shteinberg M, Shneir S, Sharma L, Saliba W. Association Between COVID-19 Infection and Pulmonary Fibrosis: A Nested Case-Control Study. The American Journal Of Medicine 2023, 136: 1087-1093.e2. PMID: 37598922, DOI: 10.1016/j.amjmed.2023.07.020.Peer-Reviewed Original ResearchPulmonary fibrosisCase-control studyCOVID-19 severityCOVID-19Multivariable conditional logistic regression modelsNested Case-Control StudyConditional logistic regression modelsSevere COVID-19Prior COVID-19COVID-19 infectionLogistic regression modelsLargest healthcare providerUnderlying cohortCohort entrySignificant morbiditySurveillance biasOdds ratioSevere diseaseFibrosisHealthcare providersCoronavirus diseaseCalendar timePatientsCohortLag timeThe Extracellular Matrix of the Human Proximal Pulmonary Artery Regulates Gene Expression of Resident Cells Responsible for Remodeling During Aging
Yuan Y, Khoury J, Ramachandra A, Singh I, Tellides G, Humphrey J, Kaminski N, Manning E. The Extracellular Matrix of the Human Proximal Pulmonary Artery Regulates Gene Expression of Resident Cells Responsible for Remodeling During Aging. 2023, a2680-a2680. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2680.Peer-Reviewed Original ResearchImpact of Adherence to Continuous Positive Airway Pressure on Outcomes in Obstructive Sleep Apnea Chronic Obstructive Pulmonary Disease Overlap Syndrome
Khoury J, Hakim F. Impact of Adherence to Continuous Positive Airway Pressure on Outcomes in Obstructive Sleep Apnea Chronic Obstructive Pulmonary Disease Overlap Syndrome. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 221-222. PMID: 36049224, PMCID: PMC9893331, DOI: 10.1164/rccm.202207-1403le.Commentaries, Editorials and Letters
2022
Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients?
Khoury J, Ghersin I, Braun E, Elias A, Aronson D, Azzam Z, Bahouth F. Adherence to Guidelines in Heart Failure, Is It Valid for Elderly Patients? Israel Medical Association Journal 2022, 24: 757-762. PMID: 36436045.Peer-Reviewed Original ResearchConceptsAcute decompensated heart failureAngiotensin receptor blockersPatients 80 yearsEjection fractionHeart failureMedicine groupSingle-center retrospective studyDecompensated heart failureReduced ejection fractionLarge prospective studiesRandomized clinical trialsOlder adult populationGDMT groupMineralocorticoid antagonistsCause mortalityReceptor blockersValue of guidelinesElderly patientsHospital dischargeOlder patientsYounger patientsMedical therapyPrimary outcomeProspective studyRetrospective studyIs all that fibrosis idiopathic? Usual interstitial pneumonia in IgG4 related disease
Khoury J, Schneer S, Sabo E, Garzuzi R, Hakrush O, Adir Y. Is all that fibrosis idiopathic? Usual interstitial pneumonia in IgG4 related disease. Respiratory Medicine And Research 2022, 82: 100971. PMID: 36403359, DOI: 10.1016/j.resmer.2022.100971.Peer-Reviewed Case Reports and Technical NotesEffectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Molnupiravir in High-Risk Patients: A Propensity Score Matched Analysis. Clinical Infectious Diseases 2022, 76: 453-460. PMID: 36130189, DOI: 10.1093/cid/ciac781.Peer-Reviewed Original ResearchConceptsSevere COVID-19Composite outcomeSevere acute respiratory syndrome coronavirus 2COVID-19-specific mortalityModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Propensity Score Matched AnalysisCOVID-19-related mortalityCOVID-19Respiratory syndrome coronavirus 2High-risk patientsTreatment of mildSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerHazard ratioVaccination statusMatched AnalysisCoronavirus 2Subgroup analysisDisease 2019High riskPositive testPatientsReply to Chen et al, Uchikoba et al, Siberry et al, and Vuorio et al
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Goldstein L, Saliba W. Reply to Chen et al, Uchikoba et al, Siberry et al, and Vuorio et al. Clinical Infectious Diseases 2022, 75: 2282-2283. PMID: 35975657, DOI: 10.1093/cid/ciac668.Commentaries, Editorials and LettersReply to Pesko et al
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Goldstein L, Saliba W. Reply to Pesko et al. Clinical Infectious Diseases 2022, 75: 2050-2050. PMID: 35869851, DOI: 10.1093/cid/ciac589.Commentaries, Editorials and LettersAwake endoscopic (esophageal) ultrasound using the endobronchial scope (EUS-B) for patients with high risk for sedation
Khoury J, Adir Y, Schneer S, Qdah M, Hakrush O, Abramovich A. Awake endoscopic (esophageal) ultrasound using the endobronchial scope (EUS-B) for patients with high risk for sedation. Respiratory Medicine And Research 2022, 82: 100944. PMID: 35878568, DOI: 10.1016/j.resmer.2022.100944.Peer-Reviewed Original ResearchImmunity waning after COVID vaccine booster vs. infection—better than expected
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Immunity waning after COVID vaccine booster vs. infection—better than expected. Infectious Diseases 2022, 54: 828-831. PMID: 35796285, DOI: 10.1080/23744235.2022.2097304.Peer-Reviewed Original ResearchConceptsBooster doseSecond doseThird doseSecond boosterBNT162b2 mRNA COVID-19 vaccineMRNA COVID-19 vaccineCOVID-19 PCRIgG antibody titresBAU/mLCOVID-19 vaccineEMMS Nazareth HospitalVaccine boosterSuggestive symptomsMean titresNasopharyngeal swabsProspective studyAsymptomatic infectionDoses groupsAntibody titresBooster groupGeneral populationHigh titresDoseTitresDosesEffectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N, Goldstein L, Saliba W. Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clinical Infectious Diseases 2022, 76: e342-e349. PMID: 35653428, PMCID: PMC9214014, DOI: 10.1093/cid/ciac443.Peer-Reviewed Original ResearchConceptsSevere COVID-19COVID-19 vaccination statusVaccination statusHazard ratioCOVID-19Severe acute respiratory syndrome coronavirus 2High-risk patients trialModerate coronavirus disease 2019Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Adjusted hazard ratioHigh-risk patientsTreatment of mildCox hazard regressionSyndrome coronavirus 2Emergency use authorizationCoronavirus disease 2019Largest healthcare providerEligible patientsOlder patientsRisk patientsHazards regressionCoronavirus 2Cardiovascular diseaseTime-dependent variablesCognitive dysfunction following COVID-19 infection
Hadad R, Khoury J, Stanger C, Fisher T, Schneer S, Ben-Hayun R, Possin K, Valcour V, Aharon-Peretz J, Adir Y. Cognitive dysfunction following COVID-19 infection. Journal Of NeuroVirology 2022, 28: 430-437. PMID: 35618983, PMCID: PMC9134977, DOI: 10.1007/s13365-022-01079-y.Peer-Reviewed Original ResearchConceptsDisease severityPulmonary function testsDetailed medical historyLong-term sequelaeCOVID-19 infectionTotal MoCA scoreMontreal Cognitive AssessmentNormal laboratory testsCognitive performancePhonemic fluencyExecutive functionAge 49.5Neurologic consultationNeurological examinationBrain CTFunction testsNeurological consultationHealthy patientsNeurologic syndromeCOVID clinicMedical historyPremorbid conditionsCognitive dysfunctionMoCA scoresMoCA test